Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 185A (TMEM185A) is a putative multi-pass membrane protein encoded by the TMEM185A gene on the X chromosome. It is primarily recognized for its genomic localization within the CpG island of the FRAXF fragile site at Xq28. This region contains a variable CGG trinucleotide repeat, which in rare cases expands but without a clear associated phenotype. The function of TMEM185A remains undefined; no clear biological activity, mechanism, or therapeutic relevance has been established to date. TMEM185A is associated genetically with Fraxf syndrome and Jacobsen syndrome, but there is no evidence that it is a direct therapeutic target, nor are there known drugs or biomarker roles for this protein[1][7][9].\n\nKey points:\n- **Transmembrane protein 185A** is not currently considered a receptor, enzyme, transporter, or direct therapeutic target.\n- Its function is not well characterized, and the association with disease is based on genomic location rather than demonstrated protein activity[1][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane protein 185A (TMEM185A).